Loading...
Market
Will Neuromap lead to the discovery of a new neuro-target by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Press releases or publications from Recursion Pharmaceuticals, Roche, or Genentech
Story
Recursion Unveils First Neuroscience Phenomap in $30 Million Collaboration with Roche and Genentech
Aug 6, 2024, 08:22 PM
Recursion Pharmaceuticals has announced the creation of the first neuroscience phenomap, called 'Neuromap,' under its collaboration with Roche and Genentech. The project, which received $30 million in funding, involved producing over one trillion hiPSC-derived neuronal cells, one of the largest datasets of its kind. This achievement marks a significant milestone in neuroscience, leveraging new genetic perturbation techniques to advance neuro-target discoveries. The Recursion team has accomplished many world firsts in this endeavor.
View original story
Similar markets
Yes • 50%
No • 50%
AI/ML algorithms • 25%
Advanced imaging techniques • 25%
Crowdsourced validation • 25%
Other • 25%
Yes • 50%
No • 50%
Yes, available for clinical trials • 25%
Yes, available for public use • 25%
No, still in development • 25%
No, project discontinued • 25%
Yes • 50%
No • 50%
1 new acquisition • 25%
2 new acquisitions • 25%
3 new acquisitions • 25%
4 or more new acquisitions • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%